Drug Trial Radar · NCT05477849
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 23, 2022
Primary completion
Oct 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Shanghai Virogin Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.
Conditions
- Advanced Malignant Solid Tumor
Interventions
Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 InjectionDrug
1. Dose level 1 2. Dose level 2 3. Dose level 3 4. Dose level 4 5. Dose level 5
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD/RP2DTime frame: During the 28 day DLT observation period
- Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.